|
|
Poly(ADP-ribose) polymerase 2 contributes to neuroinflammation and neurological dysfunction in mouse experimental autoimmune encephalomyelitis
|
|
|
|
|
نویسنده
|
kamboj a. ,lu p. ,cossoy m.b. ,stobart j.l. ,dolhun b.a. ,kauppinen t.m. ,de murcia g. ,anderson c.m.
|
منبع
|
journal of neuroinflammation - 2013 - دوره : 10 - شماره : 0
|
چکیده
|
Background: experimental autoimmune encephalomyelitis (eae) is an animal model of multiple sclerosis characterized by entry of activated t cells and antigen presenting cells into the central nervous system and subsequent autoimmune destruction of nerve myelin. previous studies revealed that non-selective inhibition of poly(adp-ribose) polymerases (parps) 1 and 2 protect against neuroinflammation and motor dysfunction associated with eae,but the role of the parp-2 isoform has not yet been investigated selectively.results: eae was induced in mice lacking parp-2,and neurological eae signs,blood-spine barrier (bsb) permeability,demyelination and inflammatory infiltration were monitored for 35 days after immunization. mice lacking parp-2 exhibited significantly reduced overall disease burden and peak neurological dysfunction. parp-2 deletion also significantly delayed eae onset and reduced bsb permeability,demyelination and central nervous system (cns) markers of proinflammatory th1 and th17 t helper lymphocytes.conclusions: this study represents the first description of a significant role for parp-2 in neuroinflammation and neurological dysfunction in eae. © 2013 kamboj et al.; licensee biomed central ltd.
|
کلیدواژه
|
CD11b; CD4; Demyelination; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Neuroinflammation; PARP-1; PARP-2; Th1; Th17
|
آدرس
|
department of pharmacology and therapeutics,university of manitoba and division of neurodegenerative disorders,st boniface hospital research,winnipeg,canada,division of neurodegenerative disorders,st boniface hospital research,winnipeg, Canada, department of pharmacology and therapeutics,university of manitoba and division of neurodegenerative disorders,st boniface hospital research,winnipeg,canada,division of neurodegenerative disorders,st boniface hospital research,winnipeg, Canada, department of internal medicine,university of manitoba,winnipeg, Canada, department of pharmacology and therapeutics,university of manitoba and division of neurodegenerative disorders,st boniface hospital research,winnipeg,canada,division of neurodegenerative disorders,st boniface hospital research,winnipeg, Canada, department of pharmacology and therapeutics,university of manitoba and division of neurodegenerative disorders,st boniface hospital research,winnipeg,canada,division of neurodegenerative disorders,st boniface hospital research,winnipeg, Canada, department of pharmacology and therapeutics,university of manitoba and division of neurodegenerative disorders,st boniface hospital research,winnipeg, Canada, dept. 'intégrité du génome' de l'umr 7175,école supérieure de biotechnologie de strasbourg,illkirch cedex, France, department of pharmacology and therapeutics,university of manitoba and division of neurodegenerative disorders,st boniface hospital research,winnipeg,canada,division of neurodegenerative disorders,st boniface hospital research,winnipeg, Canada
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|